182 related articles for article (PubMed ID: 3932684)
1. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
Soloway MS
J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
[TBL] [Abstract][Full Text] [Related]
2. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Zincke H; Benson RC; Hilton JF; Taylor WF
J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
[TBL] [Abstract][Full Text] [Related]
3. The effect of mitomycin C on superficial bladder cancer.
Soloway MS; Murphy WM; DeFuria MD; Crooke S; Finebaum P
J Urol; 1981 May; 125(5):646-8. PubMed ID: 6785454
[TBL] [Abstract][Full Text] [Related]
4. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Droller MJ; Walsh PC
J Urol; 1985 Dec; 134(6):1115-7. PubMed ID: 3932686
[TBL] [Abstract][Full Text] [Related]
5. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Soloway MS; Perry A
J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
[TBL] [Abstract][Full Text] [Related]
7. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
8. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH
Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263
[TBL] [Abstract][Full Text] [Related]
10. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin C in superficial bladder cancer: 24-month follow-up.
Somerville JJ; Newling DW; Richards B; Robinson MR; Smith PH
Br J Urol; 1985 Dec; 57(6):686-9. PubMed ID: 3936564
[TBL] [Abstract][Full Text] [Related]
12. Subsequent tumor analysis of 36 patients who have received intravesical mitomycin C for superficial bladder cancer.
Soloway MS; Ford KS
J Urol; 1983 Jul; 130(1):74-8. PubMed ID: 6408268
[TBL] [Abstract][Full Text] [Related]
13. Introduction and overview of intravesical therapy for superficial bladder cancer.
Soloway MS
Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
[TBL] [Abstract][Full Text] [Related]
14. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Baker WC; Russo MA; deVere White RW
Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
[TBL] [Abstract][Full Text] [Related]
15. Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder.
Fukui I; Sekine H; Kihara K; Yamada T; Takeuchi S; Yokokawa M; Kawai T; Hosoda K; Ohwada F; Suzuki S
J Urol; 1989 Mar; 141(3):531-4. PubMed ID: 2493099
[TBL] [Abstract][Full Text] [Related]
16. Topical mitomycin C therapy for carcinoma of the bladder.
Stricker PD; Grant AB; Hosken BM; Taylor JS
J Urol; 1987 Nov; 138(5):1164-6. PubMed ID: 3118056
[TBL] [Abstract][Full Text] [Related]
17. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
18. Severely contracted bladder following intravesical mitomycin C therapy.
Wajsman Z; McGill W; Englander L; Huben RP; Pontes JE
J Urol; 1983 Aug; 130(2):340-1. PubMed ID: 6410085
[TBL] [Abstract][Full Text] [Related]
19. Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
Wajsman Z; Dhafir RA; Pfeffer M; MacDonald S; Block A; Dragone N; Pontes JE
J Urol; 1984 Jul; 132(1):30-3. PubMed ID: 6427484
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
